Table D-3: Antipsychotic Adverse Event Profiles[o,p,q,r,s,t,u]

Medication	EPS	Sedation	Weight Gain	Metabolic	Orthostasis	AcH	QTc
Aripiprazole	++	+/0+	+/0+	+/0+	+	0	+
Asenapine	++	+	+	+	+	0	+
Brexpiprazole	++	+	0	+	+	0	+
Cariprazine	++	+	+	+	+	0	+
Chlorpromazine	++	+++	+++	++	+++	+++	++
Clozapine	+0	+++	+++	+++	+++	+++	++
Fluphenazine	+++	+	+	+	+	0	+
Haloperidol	+++	+	+	+	+	0	++
Iloperidone	+	+	++	+	+++	0	++
Loxapine	++	+	+	+	+	+	+
Lumateperone	+	+	0	+	+	+	+
Lurasidone	++	+	+	+	+	0	+
Molindone	++	++	+	+	+	+	+
Olanzapine	+	+++	+++	+++	++	++	++
Olanzapine/ Samidorphan	+	+++	++	+++	++	++	++
Paliperidone	+++	+	++	+	+	+	+
Perphenazine	++	+	++	+	++	0	+
Pimavanserin	0	+	0	0	+	++	+

[o] U.S. Package Inserts
[p] Daily Med: https://dailymed.nlm.nih.gov
[q] UpToDate: https://uptodate.com
[r] Lexicomp: https://online.lexi.com
[s] Stahl SM. Prescriber's Guide: Stahl's Essential Psychopharmacology 7th edition. New York, NY. Cambridge University Press, 2021.
[t] Keepers GA, Fochtmann LJ, Anzia JM et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 2020;177:868–872.
[u] Schoretsanitis G, Kane JM, Correll CU et al. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the therapeutic drug monitoring task force of the Arbeitsgemeinschaft fur Neuropsychopharmakologie and Pharmakopsychiatrie. J Clin Psychiatry 2020;81(3):19cs13169.